Agile SEC filing reveals FDA rejection for Twirla contraceptive
This article was originally published in Scrip
Executive Summary
Hidden deep inside a 17 March S-1 filing with the Securities and Exchange Commission (SEC) was the disclosure from Agile Therapeutics it had received a complete response letter (CRL) from the FDA for the firm's experimental once-weekly, low-dose contraceptive patch Twirla (AG200-15).
You may also be interested in...
Agile's Twirla Suffers Scathing Critique By US FDA Ahead Of Advisory Cmte.
Agile's transdermal contraceptive will go before the Bone, Reproductive and Urologic Drugs Advisory Committee as it nears the end of its third review cycle, although the agency appears ready to issue another complete response letter before it even hears from the panel.
Keeping Track: Resubmissions For Tlando And Twirla NDAs, And A BTD For Pomalyst
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: So. Much. News.
The latest drug development news and highlights from our US FDA Performance Tracker.